Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Revenue Breakdown and Options Chain

Gain deeper insights into company revenues with a detailed analysis of revenue sources.
Explore the updated Options feature, providing in-depth data, and a 3D viewing option.

Last Close
Mar 27 04:00PM ET
1.60
Dollar change
-0.02
Percentage change
-1.23
%
Index- P/E- EPS (ttm)-2.58 Insider Own4.27% Shs Outstand16.14M Perf Week1.91%
Market Cap25.82M Forward P/E- EPS next Y-0.89 Insider Trans-2.39% Shs Float15.45M Perf Month-59.70%
Income-31.59M PEG- EPS next Q-0.45 Inst Own10.71% Short Float9.39% Perf Quarter-51.52%
Sales7.10M P/S3.64 EPS this Y22.13% Inst Trans9.70% Short Ratio2.59 Perf Half Y5.26%
Book/sh-0.80 P/B- EPS next Y55.08% ROA-138.78% Short Interest1.45M Perf Year-48.19%
Cash/sh0.59 P/C2.72 EPS next 5Y- ROE-1274.20% 52W Range1.43 - 5.65 Perf YTD-59.80%
Dividend Est.- P/FCF- EPS past 5Y- ROI- 52W High-71.68% Beta0.93
Dividend TTM- Quick Ratio1.09 Sales past 5Y147.86% Gross Margin85.59% 52W Low11.89% ATR (14)0.25
Dividend Ex-Date- Current Ratio1.09 EPS Y/Y TTM17.48% Oper. Margin-435.05% RSI (14)36.70 Volatility6.64% 11.21%
Employees34 Debt/Eq- Sales Y/Y TTM146.20% Profit Margin-445.14% Recom1.00 Target Price9.33
Option/ShortYes / No LT Debt/Eq- EPS Q/Q-322.15% Payout- Rel Volume0.20 Prev Close1.62
Sales Surprise-67.67% EPS Surprise-175.45% Sales Q/Q98.18% EarningsFeb 15 BMO Avg Volume561.08K Price1.60
SMA20-9.25% SMA50-46.06% SMA200-33.34% Trades Volume112,756 Change-1.23%
Date Action Analyst Rating Change Price Target Change
Jun-05-15Reiterated Canaccord Genuity Buy $4 → $6
Jan-12-15Reiterated ROTH Capital Buy $6 → $4
May-23-12Initiated Noble Financial Buy
Jan-23-07Initiated Next Generation Buy $5
Feb-28-24 07:30AM
Feb-16-24 10:00AM
12:55AM
Feb-15-24 07:30AM
Feb-09-24 07:30AM
07:30AM Loading…
Feb-05-24 07:30AM
Feb-01-24 04:00PM
Jan-30-24 08:00AM
Jan-11-24 01:38PM
Jan-08-24 10:33AM
Jan-03-24 08:00AM
Dec-23-23 05:00PM
Dec-20-23 07:30AM
Dec-18-23 04:15PM
Nov-15-23 03:01PM
03:29AM Loading…
03:29AM
Nov-14-23 07:30AM
Nov-09-23 07:30AM
Oct-24-23 04:50PM
Oct-23-23 07:30AM
Oct-19-23 08:45AM
07:30AM
Oct-18-23 07:30AM
Oct-16-23 07:30AM
Oct-13-23 04:15PM
Oct-03-23 08:35AM
Sep-29-23 01:34AM
Sep-28-23 07:30AM
Sep-22-23 04:00PM
Sep-07-23 04:00PM
07:30AM Loading…
07:30AM
Aug-10-23 07:30AM
Aug-08-23 07:30AM
Aug-07-23 07:30AM
Aug-04-23 07:30AM
Jul-11-23 07:30AM
May-30-23 07:30AM
May-17-23 01:39PM
01:33AM
May-16-23 08:45AM
07:30AM
May-15-23 09:05AM
May-11-23 05:25PM
04:15PM
May-09-23 05:45PM
07:30AM
May-08-23 04:04PM
May-01-23 04:00PM
Apr-27-23 07:30AM
Apr-25-23 07:30AM
Apr-19-23 07:30AM
Apr-18-23 07:30AM
Mar-02-23 07:30AM
Feb-28-23 07:30AM
Feb-15-23 07:30AM
Feb-10-23 07:30AM
Jan-26-23 05:45PM
Jan-19-23 07:30AM
Jan-18-23 07:30AM
Jan-10-23 07:30AM
Jan-05-23 07:30AM
Nov-14-22 08:55AM
07:30AM
Nov-10-22 08:55AM
Nov-09-22 06:45PM
05:16PM
Nov-08-22 07:25PM
Nov-07-22 05:15PM
Oct-31-22 09:30AM
Oct-27-22 07:05AM
Oct-24-22 05:32PM
Oct-20-22 07:30AM
Oct-17-22 07:30AM
Oct-13-22 07:30AM
Sep-29-22 03:45PM
01:31PM
Sep-22-22 11:00AM
09:22AM
07:30AM
Sep-19-22 04:15PM
Sep-08-22 07:30AM
Sep-02-22 10:28AM
Aug-19-22 07:30AM
Aug-16-22 07:30AM
Jul-26-22 07:30AM
Jul-13-22 10:53AM
May-17-22 08:45AM
07:30AM
May-16-22 07:15AM
May-12-22 08:15AM
08:00AM
May-11-22 09:02AM
May-10-22 08:45AM
May-09-22 05:15PM
May-05-22 06:05PM
May-02-22 01:02PM
Apr-21-22 07:30AM
Apr-13-22 08:24AM
Mar-03-22 07:30AM
Feb-15-22 07:30AM
Palatin Technologies, Inc. is a biopharmaceutical company, which engages in the development of medicines based on molecules that modulate the activity of the melanocortin receptor system. Its primary product candidate is marketed under the Vyleesi brand, the trade name for bremelanotide, which is used for the treatment of premenopausal women with acquired, generalized, hypoactive sexual desire disorder (HSDD). The company was founded by Carl Spana and John K. A. Prendergast on November 21, 1986 and is headquartered in Cranbury, NJ.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
DEVEER ROBERT K JRDirectorMar 06 '24Sale2.0011,70023,43434,845Mar 07 05:02 PM
WILLS STEPHEN TExecutive VP and CFO/COODec 06 '23Sale2.514,99812,563327,522Dec 08 05:30 PM
DUNTON ALAN WDirectorDec 04 '23Sale2.4820049645,074Dec 06 05:02 PM